Abstract
(Abstracted from Female Pelvic Med Reconstr Surg 2018;24:404–407) Intravesical onabotulinumtoxinA (BoNT-A) is used for treatment of idiopathic overactive bladder (iOAB) when conservative measures and medications fail to improve symptoms. After intravesical BoNT-A, the risk of incomplete bladder evacuation (IBE) requiring catheterization is well established.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
